

- Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. *J Clin Oncol* 2006;24:4539–4544.
- Howlander N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute; 2013. http://seer.cancer.gov/csr/1975_2011/
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
- Varghese A, Zakowski MF, Yu HA, et al. Small-cell lung cancers in patients who never smoked cigarettes. *J Thorac Oncol* 2014;9:892–896
- Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. *J Thorac Oncol* 2009;4:37–43.
- Garfinkel L. Trends in cigarette smoking in the United States. *Prev Med* 1997;26:447–450.
- Centers for Disease Control and Prevention (CDC). Current Cigarette Smoking Among Adults – United States, 2011. *MMWR Morb Mort Wkly Rep* 2012;61:889–894.
- Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking. *J Natl Cancer Inst* 1999;91:675–690.
- Travis WD, Brambilla E, Muller-Hermelink HK, et al. *Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart*. Lyon: International Agency for Research on Cancer; 2004.
- Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. *Am J Surg Pathol* 2002;26:1184–1197.
- Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. *Mod Pathol* 2012;25:S18–S30.
- Vollmer RT. The effect of cell size on the pathologic diagnosis of small and large cell carcinomas of the lung. *Cancer* 1982;50:1380–1383.
- Hiroshima K, Iyoda A, Shida T, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. *Mod Pathol* 2006; 19:1358–1368.
- Folpe AL, Gown AM, Lamps LW, et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. *Mod Pathol* 1999;12:5–8.
- Sturn N, Lantuejoul S, Laverriere MH, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. *Hum Pathol* 2001;32:918–925.
- Sturn N, Rossi G, Lantuejoul S, et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. *Hum Pathol* 2002;33:175–182.
- Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. *Mod Pathol* 2000;13:238–242.
- Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. *Semin Oncol* 2001;28:3–13.
- Mori N, Yokota J, Akiyama T, et al. Variable mutations of the RB gene in small-cell lung carcinoma. *Oncogene* 1990;5:1713–1717.
- Arriola E, Canadas I, Arumi M, et al. Genetic changes in small cell lung carcinoma. *Clin Transl Oncol* 2008;10:189–197.
- Meuwissen R, Linn SC, Linnoila RI, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. *Cancer Cell* 2003;4:181–189.
- Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nat Genet* 2012;44:1104–1110.
- Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. *Nat Genet* 2012;44:1111–1116.
- Rekhtman N, Marchetti A, Lau C, et al. Analysis of EGFR and KRAS mutations in small cell carcinoma and large cell neuroendocrine carcinoma. Presented at: 2011 14th World Conference on Lung Cancer; July 2011; Amsterdam, The Netherlands.
- Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365:395–409.
- Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. *Cancer* 1985;56:2107–2111.
- Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). *Eur J Cancer* 1993;29A:S51–S58.
- Sculier JP, Evans WK, Feld R, et al. Superior vena caval obstruction syndrome in small cell lung cancer. *Cancer* 1986;57:847–851.
- Higgins GA, Shields TW, Keehn RJ. The solitary pulmonary nodule. Ten-year follow-up of veterans administration-armed forces cooperative study. *Arch Surg* 1975;110:570–575.
- Quoix E, Fraser R, Wolkove N, et al. Small cell lung cancer presenting as a solitary pulmonary nodule. *Cancer* 1990;66:577–582.
- Johnson DH, Hainsworth JD, Greco FA. Pancoast's syndrome and small cell lung cancer. *Chest* 1982;82:602–606.
- Leviton N, Byrne RE, Bromer RH, et al. The value of the bone scan and bone marrow biopsy staging small cell lung cancer. *Cancer* 1985;56:652–654.
- Seute T, Leffers P, ten Velde GP, et al. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. *Cancer* 2004;100:801–806.
- Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. *Oncologist* 2012;17:756–765.
- Verbalis JG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. *Eur J Endocrinol* 2011;164:725–732.
- Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. *Cancer Res* 1986;46:4189–4194.
- Shepherd FA, Laskey J, Evans WK, et al. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. *J Clin Oncol* 1992;10:21–27.
- Ilias I, Torpy DJ, Pacak K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. *J Clin Endocrinol Metab* 2005;90:4955–4962.
- Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. *N Engl J Med* 2003;349:1543–1554.
- Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. *J Clin Oncol* 1997;15:2866–2872.
- Monstad SE, Drivsholm L, Storstein A, et al. Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. *J Clin Oncol* 2004;22:795–800.
- Darnell R. Tumor immunity in small-cell lung cancer. *J Clin Oncol* 2004; 22:762–764.
- Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. *Cochrane Database Syst Rev* 2005;(2):CD003279.
- Zelen M. Keynote address on biostatistics and data retrieval. *Cancer Chemother Rep [3]* 1973;4:31–42.
- Livingston RB, McCracken JD, Trauth CJ, et al. Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. A review of the Southwest Oncology Group experience. *Chest* 1982;81:208–211.
- Albain KS, Crowley JJ, LeBlanc M, et al. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. *J Clin Oncol* 1990;8:1563–1574.
- Spiegelman D, Maurer LH, Ware JH, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. *J Clin Oncol* 1989;7:344–354.
- Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. *J Clin Oncol* 1999;17: 2681–2691.
- Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med* 1999;340:265–271.
- Doll DC. Serum lactate dehydrogenase and bone marrow involvement in small-cell carcinoma of the lung. *N Engl J Med* 1985;312:1262.
- Van den Brande P, Demedts M. Serum lactate dehydrogenase in small-cell lung cancer. *N Engl J Med* 1989;320:61.
- Kalemkerian GP, Akerley W, Bogner P, et al. Small cell lung cancer. *J Natl Compr Canc Netw* 2013;11:78–98.
- Vallieres E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol* 2009;4:1049–1059.
- Karrer K, Ulsperger E. Surgery for cure followed by chemotherapy in small cell carcinoma of the lung. For the ISC-Lung Cancer Study Group. *Acta Oncol* 1995;34:899–906.
- Kreisman H, Wolkove N, Quoix E. Small cell lung cancer presenting as a solitary pulmonary nodule. *Chest* 1992;101:225–231.
- Shepherd FA, Ginsberg RJ, Haddad R, et al. Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. *J Clin Oncol* 1993;11:1592–1597.
- Gronowitz JS, Bergstrom R, Nou E, et al. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. *Cancer* 1990;66:722–732.
- Paesmans M, Sculier JP, Lecomte J, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. *Cancer* 2000;89:523–533.
- Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. *Cancer* 2000;89:1953–1960.
- Siu LL, Shepherd FA, Murray N, et al. Influence of age on the treatment of limited-stage small-cell lung cancer. *J Clin Oncol* 1996;14:821–828.

61. Jørgensen LG, Osterlind K, Genolla J, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. *Br J Cancer* 1996;74:463–467.
62. Jara C, Gomez-Aldaravi JL, Tirado R, et al. Small-cell lung cancer in the elderly—is age of patient a relevant factor? *Acta Oncol* 1999;38:781–786.
63. Ludbrook JJ, Truong PT, MacNeil MV, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. *Int J Radiat Oncol Biol Phys* 2003;55:1321–1330.
64. Hurria A, Kris MG. Management of lung cancer in older adults. *CA Cancer J Clin* 2003;53:325–341.
65. Dearing MP, Steinberg SM, Phelps R, et al. Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. *J Clin Oncol* 1990;8:1042–1049.
66. Bremnes RM, Sundstrom S, Aasebo U, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. *Lung Cancer* 2003;39:303–313.
67. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years—an analysis of 1,714 consecutive patients. *J Clin Oncol* 1995;13:1215–1220.
68. Sagman U, Maki E, Evans WK, et al. Small-cell carcinoma of the lung: derivation of a prognostic staging system. *J Clin Oncol* 1991;9:1639–1649.
69. Videtic GM, Stitt LW, Dar AR, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. *J Clin Oncol* 2003;21:1544–1549.
70. Maestu I, Pastor M, Gomez-Codina J, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. *Ann Oncol* 1997;8:547–553.
71. Quoix E, Purohit A, Faller-Beau M, et al. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. *Lung Cancer* 2000;30:127–134.
72. Kawahara M, Fukuoka M, Saijo N, et al. Prognostic factors and prognostic staging system for small cell lung cancer. *Jpn J Clin Oncol* 1997;27:158–165.
73. Pujol JL, Quantin X, Jacot W, et al. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. *Lung Cancer* 2003;39:131–138.
74. Shingyoji M, Takiguchi Y, Watanabe R, et al. Detection of tumor specific gene expression in bone marrow and peripheral blood from patients with small cell lung carcinoma. *Cancer* 2003;97:1057–1062.
75. Laberge F, Fritsche HA, Umsawadi T, et al. Use of carcinoembryonic antigen in small cell lung cancer. Prognostic value and relation to the clinical course I. *Cancer* 1987;59:2047–2052.
76. Sculier JP, Feld R, Evans WK, et al. Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer. *J Clin Oncol* 1985;3:1349–1354.
77. Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. *J Clin Oncol* 2004;22:3248–3254.
78. Chin R Jr, McCain TW, Miller AA, et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. *Lung Cancer* 2002;37:1–6.
79. Pandit N, Gonen M, Krug L, et al. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. *Eur J Nucl Med Mol Imaging* 2003;30:78–84.
80. Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. *Lung Cancer* 2004;44:317–325.
81. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1993;11:336–344.
82. Park K, Sun J-M, Kim S-W, et al. Phase III trial of concurrent thoracic radiotherapy with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of thoracic radiotherapy for limited-disease small cell lung cancer. *J Clin Oncol* 2012;30:abstract 7004.
83. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med* 2007;357:664–672.
84. Cavalli F, Sonntag RW, Jungi F, et al. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. *Cancer Treat Rep* 1978;62:473–475.
85. Lowenbraun S, Bartolucci A, Smalley RV, et al. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. *Cancer* 1979;44:406–413.
86. Hansen HH, Dombrowsky P, Hansen M, et al. Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination. *Ann Intern Med* 1978;89:177–181.
87. Livingston RB, Moore TN, Heilbrun L, et al. Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. *Ann Intern Med* 1978;88:194–199.
88. Bunn PA Jr, Greco FA, Einhorn L. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer. *Semin Oncol* 1986;13:45–53.
89. Hong WK, Nicaise C, Lawson R, et al. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. *J Clin Oncol* 1989;7:450–456.
90. Jackson DV Jr, Case LD, Zekan PJ, et al. Improvement of long-term survival in extensive small-cell lung cancer. *J Clin Oncol* 1988;6:1161–1169.
91. Jackson DV Jr, Zekan PJ, Caldwell RD, et al. VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association. *J Clin Oncol* 1984;2:1343–1351.
92. Jett JR, Everson L, Thorneau TM, et al. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. *J Clin Oncol* 1990;8:33–38.
93. Lowenbraun S, Birch R, Buchanan R, et al. Combination chemotherapy in small cell lung carcinoma. A randomized study of two intensive regimens. *Cancer* 1984;54:2344–2350.
94. Messeih AA, Schweitzer JM, Lipton A, et al. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer. *Cancer Treat Rep* 1987;71:61–66.
95. Sierocki JS, Hilaris BS, Hopfan S, et al. cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung. *Cancer Treat Rep* 1979;63:1593–1597.
96. Evans WK, Osoba D, Feld R, et al. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. *J Clin Oncol* 1985;3:65–71.
97. Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. *J Clin Oncol* 1985;3:1471–1477.
98. Einhorn LH, Crawford J, Birch R, et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. *J Clin Oncol* 1988;6:451–456.
99. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. *J Natl Cancer Inst* 1991;83:855–861.
100. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. *J Clin Oncol* 1992;10:282–291.
101. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. *J Clin Oncol* 2002;20:4665–4672.
102. Chute JP, Venzon DJ, Hankins L, et al. Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. *Mayo Clin Proc* 1997;72:901–912.
103. Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. *Lung Cancer* 2000;30:23–36.
104. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. *Br J Cancer* 2000;83:8–15.
105. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. *Ann Oncol* 1994;5:601–607.
106. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. *J Clin Oncol* 2012;30:1692–1698.
107. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. *J Clin Oncol* 1992;10:1225–1229.
108. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. *N Engl J Med* 2002;346:85–91.
109. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. *J Clin Oncol* 2009;27:2530–2535.
110. Naka N, Kawahara M, Okishio K, et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. *Lung Cancer* 2002;37:319–323.
111. Chen G, Huynh M, Fehrenbacher L, et al. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. *J Clin Oncol* 2009;27:1401–1404.
112. Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. *J Clin Oncol* 2008;26:4261–4267.
113. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. *Cancer Res* 2000;60:6921–6926.

114. Ardizzoni A, Manegold C, Debruyne C, et al. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. *Clin Cancer Res* 2003;9:143–150.
115. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naïve patients with extensive-disease small-cell lung cancer. *J Clin Oncol* 2006;24:2044–2051.
116. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. *Cancer Treat Rep* 1982;66:439–449.
117. Ettinger DS, Finkelstein DM, Abelloff MD, et al. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. *J Clin Oncol* 1990;8:230–240.
118. Livingston RB, Mira JG, Chen TT, et al. Combined modality treatment of extensive small cell lung cancer: a Southwest Oncology Group study. *J Clin Oncol* 1984;2:585–590.
119. Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. *Ann Intern Med* 1987;107:451–458.
120. Postmus PE, Scagliotti G, Groen HJ, et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. *Eur J Cancer* 1996;32A:1498–1503.
121. Osterlind K, Sorenson S, Hansen HH, et al. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. *Cancer Res* 1983;43:6085–6089.
122. Andersen M, Kristjansen PE, Hansen HH. Second-line chemotherapy in small cell lung cancer. *Cancer Treat Rev* 1990;17:427–436.
123. Wolf M, Pritsch M, Drings P, et al. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients. *J Clin Oncol* 1991;9:614–624.
124. Aisner J, Whitacre M, Van Echo DA, et al. Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. *Cancer Treat Rep* 1982;66:221–230.
125. Ettinger DS, Lagakos S. Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lung. *Cancer* 1982;49:1544–1554.
126. Feld R, Evans WK, Coy P, et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. *J Clin Oncol* 1987;5:1401–1409.
127. Havemann K, Wolf M, Holle R, et al. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. *Cancer* 1987;59:1072–1082.
128. Urban T, Baleyte T, Chastang CL, et al. Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group. *Lung Cancer* 1999;25:105–113.
129. Loehrer PJ Sr, Rynard S, Ansari R, et al. Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer. *Cancer* 1992;69:669–673.
130. Miyamoto H, Nakabayashi T, Isobe H, et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. *Oncology* 1992;49:431–435.
131. Loehrer PJ Sr, Ansari R, Gonin R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. *J Clin Oncol* 1995;13:2594–2599.
132. Thatcher N, Lind M, Stout R, et al. Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus. *Br J Cancer* 1989;60:98–101.
133. Wolff AC, Ettinger DS, Neuberger D, et al. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. *J Clin Oncol* 1995;13:1615–1622.
134. Thatcher N, Qian W, Clark PI, et al. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. *J Clin Oncol* 2005;23:8371–8379.
135. Mavroudis D, Papadakis E, Veslemes M, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. *Ann Oncol* 2001;12:463–470.
136. Niell HB, Herndon JE 2nd, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. *J Clin Oncol* 2005;23:3752–3759.
137. Reck M, von Pawel J, Macha HN, et al. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. *J Natl Cancer Inst* 2003;95:1118–1127.
138. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party. *Br J Cancer* 1989;59:584–590.
139. Beith JM, Clarke SJ, Woods RL, et al. Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. *Eur J Cancer* 1996;32A:438–443.
140. Byrne MJ, van Hazel G, Trotter J, et al. Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial. *Br J Cancer* 1989;60:413–418.
141. Cullen M, Morgan D, Gregory W, et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. *Cancer Chemother Pharmacol* 1986;17:157–160.
142. Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. *J Clin Oncol* 1993;11:1230–1240.
143. Lebeau B, Chastang C, Allard P, et al. Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. The "Petites Cellules" Group. *Eur Respir J* 1992;5:286–290.
144. Maurer LH, Tulloh M, Weiss RB, et al. A randomized combined modality trial in small cell carcinoma of the lung: comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation. *Cancer* 1980;45:30–39.
145. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593—a phase III trial of the Eastern Cooperative Oncology Group. *J Clin Oncol* 2001;19:2114–2122.
146. Sculier JP, Paesmans M, Bureau G, et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. *J Clin Oncol* 1996;14:2337–2344.
147. Bleehen NM, Girling DJ, Machin D, et al. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party. *Br J Cancer* 1993;68:1150–1156.
148. Bleehen NM, Girling DJ, Machin D, et al. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party. *Br J Cancer* 1993;68:1157–1166.
149. Spiro SG, Souhami RL, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. *Br J Cancer* 1989;59:578–583.
150. Bozcek H, Artac M, Ozdogan M, et al. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials. *Cancer* 2005;104:2650–2657.
151. Rossi A, Garassino MC, Cinquini M, et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. *Lung Cancer* 2010;70:119–128.
152. Fruh M, De Ruyscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2013;24:vi99–vi105.
153. Teicher B. Preclinical models for high-dose therapy. In: Armitage J, Antman K, eds. *High-Dose Chemotherapy: Pharmacology, Hematopoietins, Stems Cells*. Baltimore: Williams & Wilkins; 1992.
154. Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. *N Engl J Med* 1993;329:1848–1852.
155. Cohen MH, Creaven PJ, Fossieck BE Jr, et al. Intensive chemotherapy of small cell bronchogenic carcinoma. *Cancer Treat Rep* 1977;61:349–354.
156. Figueredo AT, Hryniuk WM, Strautmanis I, et al. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. *J Clin Oncol* 1985;3:54–64.
157. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. *J Clin Oncol* 1994;12:2022–2034.
158. Johnson DH, Einhorn LH, Birch R, et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. *J Clin Oncol* 1987;5:1731–1738.
159. Pujol JL, Douillard JY, Riviere A, et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. *J Clin Oncol* 1997;15:2082–2089.
160. Steward WP, von Pawel J, Gatzemeier U, et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of VICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. *J Clin Oncol* 1998;16:642–650.
161. Lorigan P, Woll PJ, O'Brien ME, et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. *J Natl Cancer Inst* 2005;97:666–674.

162. Ardizzone A, Tjan-Heijnen VC, Postmus PE, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. *J Clin Oncol* 2002;20:3947–3955.
163. Thatcher N, Girling DJ, Hopwood P, et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. *J Clin Oncol* 2000;18:395–404.
164. Sculier JP, Paesmans M, Bureau G, et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. *J Clin Oncol* 1993;11:1858–1865.
165. Souhami RL, Rudd R, Ruiz de Elvira MC, et al. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. *J Clin Oncol* 1994;12:1806–1813.
166. Furuse K, Fukuoka M, Nishiwaki Y, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. *J Clin Oncol* 1998;16:2126–2132.
167. Murray N, Livingston RB, Shepherd FA, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Inter-group Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. *J Clin Oncol* 1999;17:2300–2308.
168. Elias A. Dose-intensive therapy in small cell lung cancer. *Chest* 1998;113:101S–106S.
169. Spitzer G, Dicke KA, Litam J, et al. High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors. *Cancer* 1980;45:3075–3085.
170. Lazarus HM, Spitzer TR, Creger RJ. Phase I trial of high-dose etoposide, high-dose cisplatin, and reinfusion of autologous bone marrow for lung cancer. *Am J Clin Oncol* 1990;13:107–112.
171. Elias AD, Ayash LJ, Wheeler C, et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. *Bone Marrow Transplant* 1995;15:373–379.
172. Littlewood TJ, Bentley DP, Smith AP. High-dose etoposide with autologous bone marrow transplantation as initial treatment of small cell lung cancer—a negative report. *Eur J Respir Dis* 1986;68:370–374.
173. Souhami RL, Hajichristou HT, Miles DW, et al. Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer. *Cancer Chemother Pharmacol* 1989;24:321–325.
174. Lange A, Kolodziej J, Tomeczko J, et al. Aggressive chemotherapy with autologous bone marrow transplantation in small cell lung carcinoma. *Arch Immunol Ther Exp (Warsz)* 1991;39:431–439.
175. Nomura F, Shimokata K, Saito H, et al. High dose chemotherapy with autologous bone marrow transplantation for limited small cell lung cancer. *Jpn J Clin Oncol* 1990;20:94–98.
176. Stahel RA, Takvorian RW, Skarin AT, et al. Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. *Eur J Cancer Clin Oncol* 1984;20:1233–1238.
177. Klastersky J, Nicaise C, Longeval E, et al. Cisplatin, adriamycin, and etoposide (CAV) for remission induction of small-cell bronchogenic carcinoma. *Cancer* 1982;50:652–658.
178. Banham S, Soukop M, Burnett A, et al. Treatment of small cell carcinoma of lung with late dosage intensification programmes containing cyclophosphamide and mesna. *Cancer Treat Rev* 1983;10:73–77.
179. Cunningham D, Banham SW, Hutcheon AH, et al. High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung. *Cancer Chemother Pharmacol* 1985;15:303–306.
180. Sculier JP, Klastersky J, Stryckmans P. Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation. *J Clin Oncol* 1985;3:184–191.
181. Spitzer G, Farha P, Valdivieso M, et al. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. *J Clin Oncol* 1986;4:4–13.
182. Ihde DC, Deisseroth AB, Lichter AS, et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. *J Clin Oncol* 1986;4:1443–1454.
183. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. *J Clin Oncol* 1987;5:1864–1873.
184. Wilson C, Pickering D, Stewart S, et al. High dose chemotherapy with autologous bone marrow rescue in small cell lung cancer. *In Vivo* 1988;2:331–334.
185. Goodman GE, Crowley J, Livingston RB, et al. Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study. *J Clin Oncol* 1991;9:453–457.
186. Elias A, Ibrahim J, Skarin AT, et al. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. *J Clin Oncol* 1999;17:1175.
187. Elias A. Hematopoietic stem cell transplantation for small cell lung cancer. *Chest* 1999;116:531S–538S.
188. Fetscher S, Brugger W, Engelhardt R, et al. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report. *Ann Oncol* 1999;10:561–567.
189. Buchholz E, Manegold C, Pilz L, et al. Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis. *J Thorac Oncol* 2007;2:51–58.
190. Ardizzone A, Hansen H, Dombrowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. *J Clin Oncol* 1997;15:2090–2096.
191. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol* 1999;17:658–667.
192. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. *J Clin Oncol* 2001;19:1743–1749.
193. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. *J Clin Oncol* 2006;24:5441–5447.
194. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. *J Clin Oncol* 2007;25:2086–2092.
195. Ettinger DS. Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific? *J Thorac Oncol* 2007;2:160–165.
196. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. *J Clin Oncol* 2008;26:5401–5406.
197. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. *J Clin Oncol* 2010;28:2598–2603.
198. Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. *J Clin Oncol* 2011;29:287–293.
199. Jotte R, Von Pawel J, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer. *J Clin Oncol* 2011;29:abstract 7000.
200. Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. *Clin Cancer Res* 2012;18:1138–1145.
201. Krug LM, Crapanzano JP, Azzoli CC, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. *Cancer* 2005;103:2128–2131.
202. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. *Cancer Res* 1996;56:370–376.
203. Krystal GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor ST1571 inhibits small cell lung cancer growth. *Clin Cancer Res* 2000;6:3319–3326.
204. Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCCTG study. *Ann Oncol* 2005;16:1811–1816.
205. Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. *Clin Cancer Res* 2003;9:5880–5887.
206. Moore SM, Rintoul RC, Walker TR, et al. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. *Cancer Res* 1998;58:5239–5247.
207. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. *Mol Cancer Ther* 2002;1:913–922.
208. Fischer B, Marinov M, Arcaro A. Targeting receptor tyrosine kinase signaling in small cell lung cancer (SCLC): what have we learned so far? *Cancer treatment reviews* 2007;33:391–406.
209. Marinov M, Ziogas A, Pardo OE, et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. *Clin Cancer Res* 2009;15:1277–1287.
210. Pandya KJ, Levy DE, Hidalgo M, et al. A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report. *J Clin Oncol* 2005;23:abstract 7005.
211. Tarhini A, Kotsakis A, Gooding W, et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. *Clin Cancer Res* 2010;16:5900–5907.
212. Belani CP, Dahlberg SE, Rudin CM, et al. Three-arm randomized phase II study of cisplatin and etoposide versus cisplatin and etoposide with either vismonegib or cixutumumab for patients with extensive-stage small cell lung cancer (ECOG 1508). *J Clin Oncol* 2013;31:abstract 7508.

213. Pepicelli CV, Lewis PM, McMahon AP. Sonic hedgehog regulates branching morphogenesis in the mammalian lung. *Curr Biol* 1998;8:1083–1086.
214. Liu H, Kho AT, Kohane IS, et al. Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development. *PLoS Med* 2006;3:e232.
215. Park KS, Martelotto LG, Peifer M, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. *Nature Med* 2011;17:1504–1508.
216. Jiang SX, Sato Y, Kuwano S, et al. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. *J Pathol* 1995;177:135–138.
217. Yan JJ, Chen FF, Tsai YC, et al. Immunohistochemical detection of Bcl-2 protein in small cell carcinomas. *Oncology* 1996;53:6–11.
218. Rudin CM, Kozloff M, Hoffman PC, et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. *J Clin Oncol* 2004;22:1110–1117.
219. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. *Ann Oncol* 2002;13:539–545.
220. Rudin CM, Salgia R, Wang X, et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. *J Clin Oncol* 2008;26:870–876.
221. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature* 2005;435:677–681.
222. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. *Cancer Res* 2007;67:1176–1183.
223. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. *Cancer Res* 2008;68:3421–3428.
224. Shoemaker AR, Mitten MJ, Adickes J, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. *Clin Cancer Res* 2008;14:3268–3277.
225. Shoemaker AR, Oleksiewicz A, Bauch J, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. *Cancer Res* 2006;66:8731–8739.
226. Kim KW, Moretti L, Mitchell LR, et al. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model. *Clin Cancer Res* 2009;15:6096–6105.
227. Tan N, Malek M, Zha J, et al. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. *Clin Cancer Res* 2011;17:1394–1404.
228. Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. *Clin Cancer Res* 2012;18:3163–3169.
229. Paik PK, Rudin CM, Pietanza MC, et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. *Lung Cancer* 2011;74:481–485.
230. Langer CJ, Albert I, Kovacs P, et al. A randomized phase II study of carboplatin and etoposide with or without pan-BCL-2 antagonist obatoclax in extensive-stage small cell lung cancer. *J Clin Oncol* 2011;29:abstract 7001.
231. Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. *J Clin Oncol* 2007;25:3945–3951.
232. Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. *J Natl Cancer Inst* 2009;101:1049–1057.
233. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. *J Clin Oncol* 2007;25:4278–4284.
234. Gillitz BJ, Moon J, Glisson BS, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. *J Thorac Oncol* 2010;5:1835–1840.
235. Ramalingam SS, Belani CP, Mack PC, et al. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). *J Thorac Oncol* 2010;5:1279–1284.
236. Heymach J, Glisson BS, Doebele RC, et al. Phase I open-label study of cediranib plus etoposide and cisplatin as first-line therapy for patients with small cell lung cancer or lung neuroendocrine cancer. *J Clin Oncol* 2010;28:abstract 7050.
237. Ready N, Pang H, Gu L, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: a randomized, placebo controlled phase II study CALGB 30504 (ALLIANCE). *J Clin Oncol* 2013;31:abstract 7506.
238. Horn L, Dahlborg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. *J Clin Oncol* 2009;27:6006–6011.
239. Ready N, Dudek AZ, Wang XF, et al. CALGB 30306: A phase II study of cisplatin, irinotecan and bevacizumab for untreated extensive stage small cell lung cancer. *J Clin Oncol* 2007;25:Abstr 7563.
240. Spigel DR, Greco FA, Zubkus JD, et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. *J Thorac Oncol* 2009;4:1555–1560.
241. Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. *J Clin Oncol* 2011;29:2215–2222.
242. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711–723.
243. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. *J Clin Oncol* 2008;26:5275–5283.
244. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. *J Clin Oncol* 2012;30:2046–2054.
245. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. *Ann Oncol* 2013;24:75–83.
246. Perry MC, Eaton WL, Probert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. *N Engl J Med* 1987;316:912–918.
247. Pignon JP, Arriagada R. Role of thoracic radiotherapy in limited-stage small-cell lung cancer: quantitative review based on the literature versus meta-analysis based on individual data. *J Clin Oncol* 1992;10:1819–1820.
248. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. *N Engl J Med* 1992;327:1618–1624.
249. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis [see comments]. *J Clin Oncol* 1992;10:890.
250. Turrisi AT 3rd, Glover DJ. Thoracic radiotherapy variables: influence on local control in small cell lung cancer limited disease. *Int J Radiat Oncol Biol Phys* 1990;19:1473–1479.
251. Roof KS, Fidas P, Lynch TJ, et al. Radiation dose escalation in limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2003;57:701–708.
252. Choi NC, Herndon JE 2nd, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. *J Clin Oncol* 1998;16:3528–3536.
253. Bogart JA, Herndon JE 2nd, Lysy AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. *Int J Radiat Oncol Biol Phys* 2004;59:460–468.
254. Miller AA, Wang XF, Bogart JA, et al. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. *J Thorac Oncol* 2007;2:645–651.
255. Carney DN, Mitchell JB, Kinsella TJ. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. *Cancer Res* 1983;43:2806–2811.
256. Ihde DC, Grayson J, Woods E, et al. Twice daily chest irradiation an adjuvant to etoposide/cisplatin therapy of limited stage small cell lung cancer. In: Salmon S, ed. *Adjuvant Therapy of Cancer*. 6th ed. Philadelphia: WB Saunders; 1990.
257. Turrisi AT 3rd, Glover DJ, Mason BA. A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. *Int J Radiat Oncol Biol Phys* 1988;15:183–187.
258. Schild SE, Bonner JA, Shanahan TG, et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2004;59:943–951.
259. Schild SE, Bonner JA, Hillman S, et al. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCCTG 95-20-53). *J Clin Oncol* 2007;25:3124–3129.
260. Langer CJ, Swann S, Werner-Wasik M, et al. Phase I study of irinotecan (ir) and cisplatin (ddp) in combination with thoracic radiotherapy (rt) either twice daily (45 Gy) or once daily (70 Gy), in patients with limited (ld) small cell lung cancer (sclc): early analysis of rtog 0241. *Proc Am Soc Clin Oncol* 2006;24:1.
261. Komaki R, Swann RS, Ettinger DS, et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. *Int J Radiat Oncol Biol Phys* 2005;62:342–350.
262. Komaki R, Paulus R, Ettinger DS, et al. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. *Int J Radiat Oncol Biol Phys* 2012;83:e531–e536.
263. Komaki R, Khalid N, Langer CJ, et al. Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. *Int J Radiat Oncol Biol Phys* 2013;85:1082–1099.
264. Spiro SG, James LE, Rudd RM, et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. *J Clin Oncol* 2006;24:3823–3830.

265. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. *J Clin Oncol* 2004;22:4837–4845.
266. De Ruyscher D, Pijls-Johannesma M, Vansteenkiste J, et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. *Ann Oncol* 2006;17:543–552.
267. Pijls-Johannesma MC, De Ruyscher D, Lambin P, et al. Early versus late chest radiotherapy for limited stage small cell lung cancer. *Cochrane Database Syst Rev* 2005;(1):CD004700.
268. Huncharek M, McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. *Oncologist* 2004;9:665–672.
269. De Ruyscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. *J Clin Oncol* 2006;24:1057–1063.
270. Kies MS, Mira JC, Crowley JJ, et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. *J Clin Oncol* 1987;5:592–600.
271. De Ruyscher D, Bremer RH, Koppe F, et al. Omission of elective node irradiation on basis of CT-scans in limited-disease small cell lung cancer: a phase II trial. *Radiation Oncol* 2006;80:307–312.
272. Videtic GM, Belderbos JS, Spring Kong FM, et al. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). *Int J Radiat Oncol Biol Phys* 2008;72:327–334.
273. Baas P, Belderbos JS, Senan S, et al. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. *Br J Cancer* 2006;94:625–630.
274. van Loon J, De Ruyscher D, Wanders R, et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. *Int J Radiat Oncol Biol Phys* 2010;77:329–336.
275. Shirvani SM, Komaki R, Heymach JV, et al. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2012;82:e91–e97.
276. Hu X, Bao Y, Zhang L, et al. Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer: interim analysis of a prospective randomized noninferiority trial. *Cancer* 2012;118:278–287.
277. Xia B, Chen GY, Cai XW, et al. Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer? *Radiation Oncol* 2012;102:258–262.
278. Colaco R, Sheikh H, Lorigan P, et al. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer—evidence from a phase II trial. *Lung Cancer* 2012;76:72–77.
279. Shirvani SM, Juloori A, Allen PK, et al. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2013;87:139–147.
280. Colaco RJ, Huh S, Nichols RC, et al. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer. *Acta Oncol* 2013;52:506–513.
281. Brooks BJ Jr, Seifter EJ, Walsh TE, et al. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. *J Clin Oncol* 1986;4:200–209.
282. Osterlind K, Hansen HH, Hansen HS, et al. Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up. *Br J Cancer* 1986;54:7–17.
283. Bunn PA Jr, Lichter AS, Makuch RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. *Ann Intern Med* 1987;106:655–662.
284. Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. *J Clin Oncol* 2002;20:3454–3460.
285. Watkins JM, Wahlquist AE, Shirai K, et al. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2009;74:1108–1113.
286. Palma DA, Senan S, Oberije C, et al. Predicting esophagitis after chemotherapy for non-small cell lung cancer: an individual patient data meta-analysis. *Int J Radiat Oncol Biol Phys* 2013;87:690–696.
287. Ettinger DS, Berkey BA, Abrams RA, et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. *J Clin Oncol* 2005;23:4991–4998.
288. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. *Int J Radiat Oncol Biol Phys* 2010;76:S70–S76.
289. Tsujino K, Hirota S, Kotani Y, et al. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: dose-volume histogram analysis and comparison with conventional chemoradiation. *Int J Radiat Oncol Biol Phys* 2006;64:1100–1105.
290. Lichter AS, Bunn PA, Ihde DC, et al. The role of radiation therapy in the treatment of small cell lung cancer. *Cancer* 1985;55:2163–2175.
291. Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. *Semin Oncol* 1988;15:278–299.
292. Livingston RB, Schulman S, Mira JC, et al. Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: a Southwest Oncology Group study. *Cancer Treat Rep* 1986;70:1395–1401.
293. Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small cell lung cancer: a randomized study. *J Clin Oncol* 1999;17:2092–2099.
294. Williams C, Alexander M, Glatstein EJ, et al. The role of radiation therapy in combination with chemotherapy in extensive oat cell cancer of the lung: a randomized study. *Cancer Treat Rep* 1977;61:1427–1431.
295. Wilson HE, Stanley K, Vincent RC, et al. Comparison of chemotherapy alone versus chemotherapy and radiation therapy of extensive small cell carcinoma of the lung. *J Surg Oncol* 1983;23:181–184.
296. Yee D, Butts C, Reiman A, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer. *Radiation Oncol* 2012;102:234–238.
297. Slotman BJ, Faivre-Finn C, van Tinteren H, et al. Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer. *J Clin Oncol* 2014; 32:5s.
298. Komaki R, Cox JD, Whitson W. Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. *Cancer Treat Rep* 1981;65:811–814.
299. Nugent JL, Bunn PA Jr, Matthews MJ, et al. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. *Cancer* 1979;44:1885–1893.
300. Rosen ST, Makuch RW, Lichter AS, et al. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Potential benefit restricted to patients with complete response. *Am J Med* 1983;74:615–624.
301. Hirsch FR, Paulson OB, Hansen HH, et al. Intracranial metastases in small cell carcinoma of the lung: correlation of clinical and autopsy findings. *Cancer* 1982;50:2433–2437.
302. Glantz MJ, Choy H, Yee L. Prophylactic cranial irradiation in small cell lung cancer: rationale, results, and recommendations. *Semin Oncol* 1997;24:477–483.
303. Einhorn LH 3rd. The case against prophylactic cranial irradiation in limited small cell lung cancer. *Semin Radiat Oncol* 1995;5:57–60.
304. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. *J Natl Cancer Inst* 1995;87:183–190.
305. Cox JD, Petrovich Z, Paig C, et al. Prophylactic cranial irradiation in patients with inoperable carcinoma of the lung. *Cancer* 1978;42:1135–1140.
306. Hansen HH, Dombrowsky P, Hirsch FR, et al. Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma: A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy. *Cancer* 1980;46:279–384.
307. Seydel HG, Creech R, Pagano M, et al. Prophylactic versus no brain irradiation in regional small cell lung carcinoma. *Am J Clin Oncol* 1985;8:218–223.
308. Auperin A, Arriagada R, Pignon J, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. *N Engl J Med* 1999;341:476–484.
309. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). *Eur J Cancer* 1997;33:1752–1758.
310. Meyers CA, Byrne KS, Komaki R. Cognitive deficits in patients with small cell lung cancer and after chemotherapy. *Lung Cancer* 1995;12:231–235.
311. Le Pechoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. *Lancet Oncol* 2009;10:467–474.
312. Fleck JF, Einhorn LH, Lauer RC, et al. Is prophylactic cranial irradiation indicated in small-cell lung cancer? *J Clin Oncol* 1990;8:209–214.
313. Johnson BE, Becker B, Goff WB, et al. Neurologic, neuropsychologic, and cranial computed tomography scan abnormalities in 2-10 year survivors of small cell lung cancer. *J Clin Oncol* 1985;3:1659–1667.
314. Lee JS, Umsawadi T, Lee Y, et al. Neurotoxicity in long-term survivors of small cell lung cancer. *Int J Radiat Oncol Biol Phys* 1986;12:313–321.
315. Johnson BE, Patronas N, Hayes W, et al. Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer: further follow-up of 6- to 13-year survivors. *J Clin Oncol* 1990;8:48–56.
316. Grosshans DR, Meyers CA, Allen PK, et al. Neurocognitive function in patients with small cell lung cancer: effect of prophylactic cranial irradiation. *Cancer* 2008;112:589–595.

317. Lee JJ, Bekele BN, Zhou X, et al. Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. *J Clin Oncol* 2006;24:3597–603.
318. Carmichael J, Crane JM, Bunn PA, et al. Results of therapeutic cranial irradiation in small cell lung cancer. *In J Radiat Oncol Biol Phys* 1988;14:455–459.
319. Harris S, Chan MD, Lovato JF, et al. Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2012;83:e53–e59.
320. Kristensen CA, Kristjansen PE, Hansen HH. Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. *J Clin Oncol* 1992;10:1498–1502.
321. Groen HJ, Smit EF, Haaxma-Reiche H, et al. Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. *Eur J Cancer* 1993;29A:1696–1699.
322. Postmus PE, Smit EF, Haaxma-Reiche H, et al. Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. *J Clin Oncol* 1995;13:660–665.
323. Postmus PE, Haaxma-Reiche H, Gregor A, et al. Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. *Radiother Oncol* 1998;46:29–32.
324. Martini N, Wittes RE, Hilaris BS, et al. Oat cell carcinoma of the lung. *Clin Bull* 1975;5:144–148.
325. Mountain CF. Clinical biology of small cell carcinoma: relationship to surgical therapy. *Semin Oncol* 1978;5:272–279.
326. Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. *Lancet* 1973;2:63–65.
327. Shields TW, Higgins GA Jr, Matthews MJ, et al. Surgical resection in the management of small cell carcinoma of the lung. *J Thorac Cardiovasc Surg* 1982;84:481–488.
328. Angeletti CA, Macchiarini P, Mussi A, et al. Influence of T and N stages on long-term survival in resectable small cell lung cancer. *Eur J Surg Oncol* 1989;15:337–340.
329. Shepherd FA, Ginsberg RJ, Feld R, et al. Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience. *J Thorac Cardiovasc Surg* 1991;101:385–393.
330. Macchiarini P, Hardin M, Basolo F, et al. Surgery plus adjuvant chemotherapy for T1-3N0M0 small-cell lung cancer. Rationale for current approach. *Am J Clin Oncol* 1991;14:218–224.
331. Rea F, Callegaro D, Favaretto A, et al. Long term results of surgery and chemotherapy in small cell lung cancer. *Eur J Cardiothorac Surg* 1998;14:398–402.
332. Lucchi M, Mussi A, Chella A, et al. Surgery in the management of small cell lung cancer. *Eur J Cardiothorac Surg* 1997;12:689–693.
333. Shepherd FA, Ginsberg RJ, Patterson GA, et al. A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer. A University of Toronto Lung Oncology Group study. *J Thorac Cardiovasc Surg* 1989;97:177–186.
334. Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. *Chest* 1994;106:320S–323S.
335. Chute JP, Chen T, Feigl E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. *J Clin Oncol* 1999;17:1794–801.
336. Merrill RM, Henson DE, Barnes M. Conditional survival among patients with carcinoma of the lung. *Chest* 1999;116:697–703.
337. Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. *J Natl Cancer Inst* 1997;89:1782–1788.
338. Kawahara M, Ushijima S, Kamimori T, et al. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. *Br J Cancer* 1998;78:409–412.
339. Heyne KH, Lippman SM, Lee JJ, et al. The incidence of second primary tumors in long-term survivors of small-cell lung cancer. *J Clin Oncol* 1992;10:1519–1524.
340. Sagman U, Lishner M, Maki E, et al. Second primary malignancies following diagnosis of small-cell lung cancer. *J Clin Oncol* 1992;10:1525–1533.
341. Sekine I, Nishiwaki Y, Kakinuma R, et al. Late recurrence of small-cell lung cancer: treatment and outcome. *Oncology* 1996;53:318–321.
342. Jacoulet P, Depierre A, Moro D, et al. Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue Francaise. *Ann Oncol* 1997;8:1009–1014.
343. Osterlind K, Hansen HH, Hansen M, et al. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. *J Clin Oncol* 1986;4:1307–1313.
344. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. *Cancer* 2003;97:934–959.
345. Harpole DH Jr, Feldman JM, Buchanan S, et al. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. *Ann Thorac Surg* 1992;54:50–54.
346. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol* 2008;26:3063–3072.
347. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. *J Clin Oncol* 2006;24:70–76.
348. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. *Chest* 2001;119:1647–51.
349. Kulke MH, Mayer RJ. Carcinoid tumors. *N Engl J Med* 1999;340:858–868.
350. Davini F, Gonfiotti A, Comin C, et al. Typical and atypical carcinoid tumours: 20-year experience with 89 patients. *J Cardiovasc Surg (Torino)* 2009;50:807–811.
351. Thomas CF Jr, Tazelaar HD, Jett JR. Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph node involvement. *Chest* 2001;119:1143–1150.
352. McCaughan BC, Martini N, Bains MS. Bronchial carcinoids. Review of 124 cases. *J Thorac Cardiovasc Surg* 1985;89:8–17.
353. Debelenko LV, Brambilla E, Agarwal SK, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. *Hum Mol Genet* 1997;6:2285–2290.
354. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. *Am J Surg Pathol* 1998;22:934–944.
355. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: Predictors of survival in 106 cases. *Hum Pathol* 2000;31:1255–1265.
356. Pelosi G, Rodriguez J, Viale G, et al. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. *Am J Surg Pathol* 2005;29:179–187.
357. Davies SJ, Gosney JR, Hansell DM, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. An under recognised spectrum of disease. *Thorax* 2007;62:248–252.
358. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. *N Engl J Med* 2006;355:1763–1771.
359. Chughthai TS, Morin JE, Sheiner NM, et al. Bronchial carcinoid—twenty years' experience defines a selective surgical approach. *Surgery* 1997;122:801–808.
360. Limper AH, Carpenter PC, Scheithauer B, et al. The Cushing syndrome induced by bronchial carcinoid tumors. *Ann Intern Med* 1992;117:209–214.
361. Athanassiadi K, Exarchos D, Tsagarakis S, et al. Acromegaly caused by ectopic growth hormone-releasing hormone secretion by a carcinoid bronchial tumor: a rare entity. *J Thorac Cardiovasc Surg* 2004;128:631–632.
362. Yellin A, Zwas ST, Rozenman J, et al. Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors. *Isr Med Assoc J* 2005;7:712–716.
363. Granberg D, Sundin A, Janson ET, et al. Octreoscan in patients with bronchial carcinoid tumours. *Clin Endocrinol (Oxf)* 2003;59:793–799.
364. Erasmus JJ, McAdams HP, Patz EF Jr, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. *AJR Am J Roentgenol* 1998;170:1369–1373.
365. Daniels CE, Lowe VJ, Aubry MC, et al. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. *Chest* 2007;131:255–260.
366. Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using ⁶⁸Ga-DOTA-TATE (DOTA-DPhe1,Tyr3-octreotate) and ¹⁸F-FDG. *Cancer* 2008;112:2447–2455.
367. Binderup T, Knigge U, Loft A, et al. ¹⁸F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. *Clin Cancer Res* 2010;16:978–985.
368. Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. *Ann Oncol* 2001;12:1383–1391.
369. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? *J Clin Oncol* 2007;25:1967–1973.
370. Travis WD, Giroux DJ, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. *J Clin Oncol* 2008;3:1213–1223.
371. Yendamuri S, Gold D, Jayaprakash V, et al. Is sublobar resection sufficient for carcinoid tumors? *Ann Thorac Surg* 2011;92:1774–1778.
372. Marty-Ane CH, Costes V, Pujol JL, et al. Carcinoid tumors of the lung: do atypical features require aggressive management? *Ann Thorac Surg* 1995;59:78–83.
373. Garcia-Yuste M, Matilla JM, Cueto A, et al. Typical and atypical carcinoid tumors: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumors of the Lung. *Eur J Cardiothorac Surg* 2007;31:192–197.
374. Cardillo G, Sera F, Di Martino M, et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. *Ann Thorac Surg* 2004;77:1781–1785.
375. Mineo TC, Guggino G, Mineo D, et al. Relevance of lymph node micrometastases in radically resected endobronchial carcinoid tumors. *Ann Thorac Surg* 2005;80:428–432.
376. Wurtz A, Benhamed L, Conti M, et al. Results of systematic nodal dissection in typical and atypical carcinoid tumors of the lung. *J Thorac Oncol* 2009;4:388–394.
377. Ferolla P, Daddi N, Urbani M, et al. Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids. *J Thorac Oncol* 2009;4:383–387.

378. Kalemkerian GP, Akerley W, Blum MG, et al. Practice Guidelines: Small Cell Lung Cancer. 2010 (accessed May 8, 2010).
379. Lou F, Sarkaria I, Pietanza C, et al. Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. *Ann Thorac Surg* 2013;96:1156–1162.
380. Wirth LJ, Carter MR, Janne PA, et al. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. *Lung Cancer* 2004;44:213–220.
381. Mackley HB, Videtic GM. Primary carcinoid tumors of the lung: a role for radiotherapy. *Oncology (Williston Park)* 2006;20:1537–1543.
382. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. *Cancer Clin Trials* 1979;2:327–334.
383. Filosso PL, Ruffini E, Oliaro A, et al. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. *Eur J Cardiothorac Surg* 2002;21:913–917.
384. Srirajaskanthan R, Toumpanakis C, Karpathakis A, et al. Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. *Lung Cancer* 2009;65:68–73.
385. Forde PM, Hooker CM, Boikos SA, et al. Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report. *J Thorac Oncol* 2014;9:414–418.
386. Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. *Gastroenterology* 2005;128:1717–1751.
387. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol* 2009;27:4656–4663.
388. Gridelli C, Rossi A, Airoma G, et al. Treatment of pulmonary neuroendocrine tumours: state of the art and future developments. *Cancer Treat Rev* 2013;39:466–472.
389. Detterbeck FC. Management of carcinoid tumors. *Ann Thorac Surg* 2010;89:998–1005.
390. Fjallskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. *Cancer* 2001;92:1101–1107.
391. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. *Clin Cancer Res* 2007;13:2986–2991.
392. Saranga-Perry V, Morse B, Centeno B, et al. Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series. *Neuroendocrinology* 2013;97:318–321.
393. Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. *Cancer Chemother Pharmacol* 2013;71:663–670.
394. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. *J Clin Oncol* 2006;24:401–406.
395. Kulke MH, Stuart K, Earle CC, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. *J Clin Oncol* 2006;24:4044.
396. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. *Lancet* 2011;378:2005–2012.
397. Reidy-Lagunes D, Thornton R. Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different? *Curr Oncol Rep* 2012;14:249–256.
398. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. *J Clin Oncol* 2008;26:1316–1323.
399. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. *J Clin Oncol* 2008;26:3403–3410.
400. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:501–513.
401. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. *Cancer* 2005;104:1590–1602.
402. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. *Cancer* 1991;68:227–232.
403. Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. *J Clin Oncol* 2005;23:4897–4904.
404. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. *Am J Surg Pathol* 1991;15:529–553.
405. Travis WD, Krug LM, Rusch V, et al. Large Cell Neuroendocrine Carcinoma. *Textbook of Uncommon Cancer*. Chichester, England: John Wiley & Sons, Ltd.; 2006: 298–306.
406. Chen LC, Travis WD, Krug LM. Pulmonary neuroendocrine tumors: What (little) do we know? *J Natl Compr Canc Netw* 2006;4:623–630.
407. Travis WD. Neuroendocrine lung tumors. *Path Case Reviews* 2006;11:235–242.
408. Rossi G, Cavazza A, Marchioni A, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. *J Clin Oncol* 2005;23:8774–8785.
409. Oshiro Y, Kusumoto M, Matsuno Y, et al. CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients. *AJR Am J Roentgenol* 2004;182:87–91.
410. Chong S, Lee KS, Kim BT, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. *AJR Am J Roentgenol* 2007;188:1223–1231.
411. Takei H, Asamura H, Maeshima A, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. *J Thorac Cardiovasc Surg* 2002;124:285–292.
412. Veronesi G, Morandi U, Alloisio M, et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. *Lung Cancer* 2006;53:111–115.
413. Iyoda A, Hiroshima K, Toyozaki T, et al. Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. *Cancer* 2001;92:1108–1112.
414. Sarkaria IS, Iyoda A, Roh MS, et al. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. *Ann Thorac Surg* 2011;92:1180–1186.
415. Zacharias J, Nicholson AG, Ladas GP, et al. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection. *Ann Thorac Surg* 2003;75:348–352.
416. Saiji H, Tsuboi M, Matsubayashi J, et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. *Anticancer Drugs* 2010;21:89–93.
417. Tanaka Y, Ogawa H, Uchino K, et al. Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma: a possible association between staining patterns with neuroendocrine markers and tumor response to chemotherapy. *J Thorac Cardiovasc Surg* 2013;145:839–846.
418. Iyoda A, Hiroshima K, Moriya Y, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. *Ann Thorac Surg* 2006;82:1802–1807.
419. Iyoda A, Hiroshima K, Moriya Y, et al. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. *J Thorac Cardiovasc Surg* 2009;138:446–453.
420. Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer, version 2. *J Natl Compr Canc Netw*. 2013;11:645–653, quiz 653.
421. Yamazaki S, Sekine I, Matsuno Y, et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. *Lung Cancer* 2005;49:217–223.
422. Sun JM, Ahn MJ, Ahn JS, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? *Lung Cancer* 2012;77:365–370.
423. Niho S, Kenmotsu H, Sekine I, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. *J Thorac Oncol* 2013;8:980–984.
424. Le Treut J, Sault MC, Lena H, et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. *Ann Oncol* 2013;24:1548–1552.
425. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. *J Clin Oncol* 2006;24:2038–2043.
426. Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. *Br J Cancer* 1998;77:347–351.
427. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. *Eur J Cancer* 1994;30A:1058–1060.
428. Masters GA, Declercq L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. *J Clin Oncol* 2003;21:1550–1555.
429. Hoang T, Kim K, Jaslowski A, et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. *Lung Cancer* 2003;42:97–102.
430. van der Lee I, Smit EF, van Putten JW, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. *Ann Oncol* 2001;12:557–561.
431. Furuse K, Kubota K, Kawahara M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. *Oncology* 1996;53:169–172.
432. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. *Eur J Cancer* 1993;29A:1720–1722.

433. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. *J Clin Oncol* 2006;24:5448–5453.
434. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. *J Clin Oncol* 2010;28:2598–2603.
435. Treat J, Schiller J, Quoix E, et al. ZD0473 treatment in lung cancer: an overview of the clinical trial results. *Eur J Cancer* 2002;38:S13–S18.
436. Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. *J Clin Oncol* 2009;27:2046–2051.
437. Ciuleanu T, Samarzija M, Demidchik Y, et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care or best supportive care alone in patients with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. *J Clin Oncol* 2010;28:abstract 7002.
438. Mattson K, Niiranen A, Pyrhonen S, et al. Natural interferon alfa as maintenance therapy for small cell lung cancer. *Eur J Cancer* 1992;28A:1387–1391.
439. Prior C, Oroszy S, Oberaigner W, et al. Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial. *Eur Respir J* 1997;10:392–396.
440. Ruotsalainen TM, Halme M, Tamminen K, et al. Concomitant chemotherapy and IFN-alpha for small cell lung cancer: a randomized multicenter phase III study. *J Interferon Cytokine Res* 1999;19:253–259.
441. Kelly K, Crowley JJ, Bunn PA Jr, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. *J Clin Oncol* 1995;13:2924–2930.
442. Jett JR, Maksymiuk AW, Su JQ, et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. *J Clin Oncol* 1994;12:2321–2326.
443. van Zandwijk N, Groen HJ, Postmus PE, et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. *Eur J Cancer* 1997;33:1759–1766.
444. Clamon G, Herndon J, Perry MC, et al. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. *J Natl Cancer Inst* 1993;85:316–320.
445. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. *JAMA* 1981;245:831–835.
446. Chahinian AP, Probert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. *J Clin Oncol* 1989;7:993–1002.
447. Lebeau B, Chastang C, Muir JF, et al. No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The “Petites Cellules” Group. *Cancer* 1993;71:1741–1745.
448. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. *Cancer* 1994;74:38–45.
449. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. *J Clin Oncol* 2002;20:4434–4439.
450. Rigas JR, Denham CA, Rinaldi DA, et al. Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer. *Proc Am Soc Clin Oncol* 2003;22:Abstr 2525.
451. Heymach JV, Johnson DH, Khuri FR, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. *Ann Oncol* 2004;15:1187–1193.
452. Lara PN Jr, Chansky K, Davies AM, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). *J Thorac Oncol* 2006;1:996–1001.
453. Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bc2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). *J Clin Oncol* 2005;23:6854–6864.